Modulating Spinal Interoceptive Pathways to Evaluate Their Role and Therapeutic Potential in MDD Symptomatic Domains

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

67 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-02-25

Study Completion Date

2026-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Spinal interoceptive pathways (SIPs) convey bodily signals to an interoceptive system in the brain and their dysregulation is linked to major depressive disorder (MDD). Current treatments are partially effective and the role of SIPs in MDD is vastly unexplored. Preliminary data suggests that SIPs are feasible therapeutic targets in MDD. The central hypothesis is that non-invasive spinal cord stimulation will modulate SIPs to elucidate their role and therapeutic potential in MDD using an R61/33 phased innovation approach.

R61 phase specific aims (SA). The specific goal will be to evaluate spinal and brain-based SIPs target engagement markers of transcutaneous spinal direct current stimulation (tsDCS) in MDD with two SAs: SA1) To determine tsDCS SIPs modulation using laser-evoked potentials (LEPs) as electroencephalography (EEG)- based neural measures of target engagement. SA2) To evaluate optimal tsDCS dose based upon tolerability and SIPs target engagement markers. Anodal tsDCS will be evaluated as a tool to modulate SIPs in MDD. SIPs (Aδ and C fibers) can be evaluated via LEPs as neural measures (EEG) elicited in MDD-relevant brain regions within an interoceptive system. Prior data shows anodal tsDCS inhibits SIPs and LEPs N2 component will be assessed as tsDCS engagement markers. Adults with MDD (n=67) will participate in a double-blind, crossover, sham-controlled study to evaluate tsDCS at 0,2.5,3, and 3.5 mA. The working hypothesis is that tsDCS will induce a change in LEPs (SA1) in a dose-dependent and tolerable manner (SA2), supporting their use as SIPs engagement markers. Go/No-Go milestones: Compared to sham, the active tsDCS dose that induces a change in LEPs at a preestablished threshold will be evidence of SIPs engagement and "Go" criteria for the R33 phase.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Spinal Cord Stimulation for the Treatment of Major Depressive Disorder

NCT03433339

Major Depressive Disorder

COMPLETED PHASE1/PHASE2

Deep Brain Stimulation (DBS) for Treatment-Resistant Depression (TRD)

NCT01898429

Treatment Resistant Depression Depressive Disorder, Treatment-Resistant Depression, Bipolar

COMPLETED NA

Intensive tDCS for MDD: Feasibility Study

NCT05194267

Major Depressive Disorder

COMPLETED NA

Home-based Transcranial Direct Current Stimulation (tDCS) for Major Depressive Disorders (MDD)

NCT05205915

Major Depressive Disorder

UNKNOWN NA

Deciphering Principles of Network Dynamics Underlying Depression Symptom Severity From Multi-day Intracranial Recordings in Patients With Major Depression

NCT06953362

Treatment Resistant Depression

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depression - Major Depressive Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

2.0 Sham

Sham will also be compared to "No intervention"

Group Type SHAM_COMPARATOR

transcutaneous spinal direct current stimulation

Intervention Type DEVICE

transcutaneous spinal direct current stimulation

2.5 Active

Group Type ACTIVE_COMPARATOR

transcutaneous spinal direct current stimulation

Intervention Type DEVICE

transcutaneous spinal direct current stimulation

3.0 Active

Group Type ACTIVE_COMPARATOR

transcutaneous spinal direct current stimulation

Intervention Type DEVICE

transcutaneous spinal direct current stimulation

3.5 Active

Group Type ACTIVE_COMPARATOR

transcutaneous spinal direct current stimulation

Intervention Type DEVICE

transcutaneous spinal direct current stimulation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

transcutaneous spinal direct current stimulation

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 to 60 yrs., inclusive,
* Female or Male,
* With current MDD episode according to MINI 7.0.2. duration (≥4 weeks and

≤ 2 yrs.),
* Current BMI ≥18.5 and ≤ 35 kg/mts2, inclusive,
* MADRS score at screening ≥18
* Currently on an FDA- approved antidepressant medication at a stable therapeutic dose for ≥ 8 weeks,
* Psychotherapeutic interventions are allowed if dose/frequency stable for ≥4 weeks,
* Anxiety disorders allowed if no more than moderate in severity and are not the main diagnosis,
* Using an effective contraceptive method (participants with childbearing potential), and 10)Able to complete study related tasks.

Exclusion Criteria

* Treatment resistance during current depressive episode (\>2 treatment trials at adequate doses/duration), including medication and neuromodulation treatments.
* Current/lifetime diagnosis of bipolar disorder or schizophrenia spectrum disorders.
* Significant risk of suicide according to CSSRS or clinical judgment, or suicidal behavior in the past year.
* Psychotic symptoms during the current MDD episode or in the past 6 months.
* Current (past month) substance use disorder (nicotine, caffeine allowed).
* Current unstable neurological conditions including seizure disorders (infantile seizures are not exclusionary), neurodegenerative disorders, or stroke.
* Evidence of severe peripheral neuropathy.
* History of moderate to severe traumatic brain injury (e.g., skull fracture or loss of consciousness \>10 minutes) or spinal cord injury.
* Unstable clinically significant medical conditions (e.g., uncontrolled hypertension as indicated by a systolic \>150 mmHg or diastolic \>95mmHg).
* History of cancer allowed if remitted for the past 5 years.
* Use of anticonvulsant medications and calcium channel blockers at screening.
* Current severe pain conditions or need for chronic use of pain medication including NSAIDs and opiates.
* Implanted electronic medical devices.
* Neuromodulation interventions in the past month.
* Active skin lesions on electrode placement sites.
* pregnant or breastfeeding.
* Suspected IQ \<80.
* Any other relevant clinical reason as judged by the clinician.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No